-

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into the Fairness of the Proposed Buyout of Cvent Holding Corp. (CVT) Shareholders at $8.50 Per Share and Encourages Long-Term CVT Investors to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating the fairness of the recently announced go-private transaction of Cvent Holding Corp. (NASDAQ: CVT) (“Cvent”) on behalf of the company’s investors.

On March 14, 2023, Cvent reported that it would be acquired by private equity funds managed by Blackstone at a price of $8.50 per share. Following the closing of the proposed transaction, Cvent investors will be cashed out of their investment position and the company’s shares will no longer be publicly traded.

The investigation seeks to determine whether $8.50 per share represents appropriate and sufficient consideration for Cvent shares, and whether the company’s officers and/or directors violated the securities laws or breached their fiduciary duties in agreeing to sell the company to Blackstone at that price.

Cvent shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (888) 715 – 1740, or by email (skaskela@kaskelalaw.com / abell@kaskelalaw.com) or online at https://kaskelalaw.com/cases/cvent-holding-corp/, for additional information about this investigation and their legal rights and options.

Kaskela Law LLC represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

This notice may constitute attorney advertising in certain jurisdictions.

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com

Kaskela Law LLC

NASDAQ:CVT

Release Versions

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com

More News From Kaskela Law LLC

Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company’s current shareholders. The investigation seeks to determine whether Amneal or the company’s officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions. Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional infor...

Kaskela Law Firm Announces Investigation of DexCom, Inc. (DXCM) and Encourages Long-Term DXCM Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company’s long-term investors. Click here for additional information: https://kaskelalaw.com/case/dexcom-inc/ Recently a securities fraud complaint was filed against DexCom on behalf of investors who purchased shares of the company's stock between January 8, 2024 and September 17, 2025 (the “Wrongdoing Period”). According to the complaint, during th...

Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc. (FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Fortrea Holdings Inc. (Nasdaq: FTRE) (“Fortrea”) on behalf of the company’s long-term investors. Click here for additional information: https://kaskelalaw.com/case/fortrea-holdings/ Recently a securities fraud complaint was filed against Fortrea on behalf of certain investors who purchased shares of the company’s stock between July 5, 2023 and February 28, 2025 (the “Wrongdoing Period”). Accor...
Back to Newsroom